PortfoliosLab logo
Agenus Inc. (AGEN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00847G7051

CUSIP

00847G705

IPO Date

Feb 4, 2000

Highlights

Market Cap

$95.10M

EPS (TTM)

-$10.59

Total Revenue (TTM)

$75.46M

Gross Profit (TTM)

$246.00K

EBITDA (TTM)

-$70.69M

Year Range

$1.38 - $19.69

Target Price

$6.00

Short %

15.08%

Short Ratio

5.18

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
AGEN vs. ETHSX AGEN vs. VOO
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period

Agenus Inc. (AGEN) returned 23.36% year-to-date (YTD) and -69.52% over the past 12 months. Over the past 10 years, AGEN returned -30.93% annually, underperforming the S&P 500 benchmark at 10.77%.


AGEN

YTD

23.36%

1M

98.82%

6M

8.86%

1Y

-69.52%

5Y*

-40.52%

10Y*

-30.93%

^GSPC (Benchmark)

YTD

0.08%

1M

9.75%

6M

-1.63%

1Y

12.74%

5Y*

15.66%

10Y*

10.77%

*Annualized

Monthly Returns

The table below presents the monthly returns of AGEN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202538.69%-25.00%-47.19%92.03%16.96%23.36%
2024-19.41%0.42%-13.43%4.48%29.46%6.76%-63.94%-14.74%6.41%-23.36%-18.57%-19.88%-83.45%
20238.75%-21.07%-26.21%1.23%3.31%2.56%-5.00%-9.21%-18.12%-29.20%-2.86%6.54%-64.85%
2022-14.29%-2.17%-8.89%-24.80%-9.73%16.17%32.99%4.65%-24.07%22.44%7.57%-11.11%-25.47%
202115.72%8.70%-32.00%13.60%37.86%28.87%-5.65%19.11%-14.91%-26.86%-17.97%2.22%1.26%
2020-8.11%-32.35%-3.16%8.78%39.96%5.36%-22.65%43.26%-8.15%-7.75%0.27%-14.05%-21.87%
201941.60%-8.31%-3.88%-13.47%-0.78%17.65%-19.67%19.50%-10.42%0.39%61.78%-2.86%71.01%
201810.74%49.31%-12.62%-27.18%-2.33%-32.24%-19.38%20.76%-3.17%-25.70%51.57%-1.24%-26.99%
2017-2.91%6.00%-11.08%-4.77%-7.52%17.77%13.56%-16.89%19.51%-17.01%7.38%-17.05%-20.87%
2016-30.62%-12.06%50.18%-15.38%19.89%-4.03%37.04%11.53%15.99%-44.71%3.78%0.00%-9.25%
201526.70%-2.58%4.69%28.85%23.75%5.50%-1.04%-16.74%-35.30%-0.87%12.06%-11.15%14.36%
201417.05%58.25%-35.17%-10.41%6.34%6.62%2.48%-4.85%-0.96%-4.18%-0.67%34.12%50.38%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AGEN is 19, meaning it’s performing worse than 81% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of AGEN is 1919
Overall Rank
The Sharpe Ratio Rank of AGEN is 1818
Sharpe Ratio Rank
The Sortino Ratio Rank of AGEN is 2121
Sortino Ratio Rank
The Omega Ratio Rank of AGEN is 2121
Omega Ratio Rank
The Calmar Ratio Rank of AGEN is 88
Calmar Ratio Rank
The Martin Ratio Rank of AGEN is 2525
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Agenus Inc. (AGEN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Agenus Inc. Sharpe ratios as of May 14, 2025 (values are recalculated daily):

  • 1-Year: -0.60
  • 5-Year: -0.44
  • 10-Year: -0.38
  • All Time: -0.31

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Agenus Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Agenus Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Agenus Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Agenus Inc. was 99.98%, occurring on Mar 31, 2025. The portfolio has not yet recovered.

The current Agenus Inc. drawdown is 99.95%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.98%Feb 7, 20006325Mar 31, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Agenus Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Agenus Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 48.0% positive surprise.


-3.00-2.00-1.000.001.0020212022202320242025
-1.03
-1.98
Actual
Estimate

Valuation

The Valuation section provides an overview of how Agenus Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for AGEN compared to other companies in the Biotechnology industry. AGEN currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AGEN relative to other companies in the Biotechnology industry. Currently, AGEN has a P/S ratio of 0.9. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AGEN in comparison with other companies in the Biotechnology industry. Currently, AGEN has a P/B value of 218.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items